Includes all of these presentations from this session:
||Is carginogenesis in Barrett’s esophagus a clonal evolution?
||K.M. Das (New Brunswick)
||Molecular Markers: “predictive” vs. “prognostic” vs. “signaling”. What is the difference?
||J. Gibson (New Haven)
||Research funding should be considered only if the biomarkers demonstrate a high potential for clinical relevance: Yes or No!
||I. Parker (Cape Town)
||Research funding should be considered even if the biomarkers have yet to demonstrate potential for clinical relevance. Yes or No!
||T.E Godfrey (Boston)
||The absolutely perfect biomarker for early detection of esophageal cancer: How would it affect morbidity & mortality?
||H. Mashimo (Boston)
||The absolutely perfect biomarker for treatment of esophageal cancer: How would it affect morbidity and mortality?
||W. El-Rifai (Nashville)
||Targeting Esophageal Cancer: A Genome Based Strategy
||L. Mishra (Houston)
||Will we ever succeed? Putting it all together
||S.J. Sontag (Chicago)